July 30, 2026 at 6:30 AM EDT PDF Version Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net…
July 30, 2026 at 6:30 AM EDT
PDF Version
-
Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025
-
Dupixent® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion
-
EYLEA HD® U.S. net sales increased 52% to a new all-time high of $596 million
-
Libtayo® global net sales increased 30% to a new all-time high of $489 million
-
GAAP EPS of $12.23, including $1.02 negative impact from IPR&D; non-GAAP EPS(a) of $14.29, including $0.99 negative impact from IPR&D
-
Sanofi Development Balance fully repaid as of end of second quarter 2026
-
Cemdisiran regulatory submissions accepted for review by FDA and EMA for treatment of generalized myasthenia gravis (gMG)
TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the second quarter of 2026 and provided a business update.
"Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. "Of note, global Dupixent, global Libtayo, and U.S. EYLEA HD net product sales increased by 38%, 30%, and 52%, respectively, compared to the second quarter of 2025. With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases."
Financial Highlights
| ($ in millions, except per share data) | | Q2 2026 | | Q2 2025 | | % Change |
| Total revenues | | $ | 4,291 | | | $ | 3,676 | | | 17 | % |
| GAAP net income | | $ | 1,297 | | | $ | 1,392 | | | (7 | %) |
| GAAP net income per share - diluted | | $ | 12.23 | | | $ | 12.81 | | | (5 | %) |
| Non-GAAP net income(a) | | $ | 1,543 | | | $ | 1,424 | | | 8 | % |
| Non-GAAP net income per share - diluted(a) | | $ | 14.29 | | | $ | 12.89 | | | 11 | % |
| |
"Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures," said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "By the end of the second quarter, we had fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for their funding of prior collaboration development activities. The repayment of this obligation will drive a meaningful step-up in collaboration profits beginning in the third quarter. Given our strong financial position, we continue to invest confidently in our pipeline, U.S. manufacturing, and external innovation, while returning capital to shareholders, reflected by the nearly $3.0 billion deployed in the first half of the year to share repurchases, dividends, capital expenditures, and business development."
Business Highlights
Key Pipeline Progress
Regeneron has approximately 50 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications. Updates from the clinical pipeline include:
Dupixent (dupilumab)
- In April 2026, the U.S. Food and Drug Administration (FDA) and European Commission approved Dupixent for the treatment of chronic spontaneous urticaria (CSU), expanding the eligible population to include children aged 2 to 11 years who remain symptomatic despite antihistamine treatment.
EYLEA HD (aflibercept) 8 mg
- In April 2026, the FDA approved the extension of dosing intervals for EYLEA HD up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following one year of successful response based on visual and anatomic outcomes.
Otarmeni™ (lunsotogene parvec, formerly known as DB-OTO)
- In May 2026, the European Medicines Agency (EMA) accepted for review, under accelerated assessment, the Marketing Authorization Application (MAA) for Otarmeni for the treatment of biallelic OTOF variant-associated hearing loss.
Fianlimab (LAG-3 antibody)
- In May 2026, the Company announced results from the Phase 3 trial evaluating two dose levels of fianlimab in combination with cemiplimab as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma. The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab monotherapy.
Other Programs
-
In June 2026, the Company announced that both the FDA and EMA have accepted the regulatory applications for cemdisiran (C5 RNAi therapy) to treat adult patients with gMG. The FDA will review the New Drug Application (NDA) under priority review with a target action date in November 2026, following use of a Priority Review Voucher. A decision from the European Commission is anticipated in the second half of 2027.
-
The Company announced positive results from the Phase 1/2 LINKER-AL2 trial for Lynozyfic® (linvoseltamab) in adults with second-line-plus systemic amyloid light chain amyloidosis. The results were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The Phase 2 portion of the trial with registrational intent, part of a broad clinical development program investigating Lynozyfic, is underway.
-
A Phase 3 study was initiated in peripheral artery disease (PAD) for cenvacibart (REGN7508, an antibody to Factor XI (catalytic domain)), and amrecibart (REGN9933, an antibody to Factor XI (A2 domain)), to evaluate each antibody individually compared to standard of care.
Corporate Updates
-
The FDA selected the Company's manufacturing facility in Saratoga Springs, New York, which is currently under construction, to participate in the FDA PreCheck Pilot Program. The FDA PreCheck Pilot Program is intended to support the development of new U.S. pharmaceutical manufacturing facilities by encouraging earlier FDA engagement and providing a more predictable regulatory pathway.
-
In May 2026, the Company entered into a collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis’ Helicon™ peptide platform.
-
The Company announced that it had been named to the Dow Jones Best-in-Class World Index, one of the world’s most recognized benchmarks for corporate sustainability performance, for the seventh consecutive year.
Second Quarter 2026 Financial Results
Revenues
| ($ in millions) | | Q2 2026 | | Q2 2025 | | % Change |
| Net product sales: | | | | | | | | |
| EYLEA HD - U.S. | | $ | 596 | | | $ | 393 | | | 52 | % |
| EYLEA®- U.S. | | | 412 | | | | 754 | | | (45 | %) |
| Total EYLEA HD and EYLEA - U.S. | | | 1,008 | | | | 1,147 | | | (12 | %) |
| Libtayo - U.S. | | | 343 | | | | 248 | | | 38 | % |
| Libtayo - ROW* | | | 146 | | | | 129 | | | 13 | % |
| Total Libtayo - Global | | | 489 | | | | 377 | | | 30 | % |
| Praluent®- U.S. | | | 75 | | | | 66 | | | 14 | % |
| Evkeeza®- U.S. | | | 53 | | | | 41 | | | 29 | % |
| Lynozyfic®- Global | | | 17 | | | | — | | | ** | |
| Total net product sales | | | 1,642 | | | | 1,631 | | | 1 | % |
| | | | | | | | | |
| Collaboration revenue: | | | | | | | | |
| Sanofi | | | 2,174 | | | | 1,444 | | | 51 | % |
| Bayer | | | 276 | | | | 415 | | | (33 | %) |
| Other | | | 6 | | | | 2 | | | ** | |
| Other revenue | | | 193 | | | | 184 | | | 5 | % |
| Total revenues | | $ | 4,291 | | | $ | 3,676 | | | 17 | % |
| | | | | | | | | |
| * Rest of world (ROW) |
| ** Percentage not meaningful or greater than 100% |
| |
Net product sales of EYLEA HD increased in the second quarter of 2026, compared to the second quarter of 2025, primarily due to higher sales volumes driven by increased demand, partly offset by a lower net selling price.
Net product sales of EYLEA in the second quarter of 2026, compared to the second quarter of 2025, were negatively impacted by (i) lower sales volumes, driven by decreased demand, as a result of continued competitive pressures and the continued transition of patients to EYLEA HD, and (ii) a lower net selling price.
Global net product sales of Libtayo increased in the second quarter of 2026, compared to the second quarter of 2025, primarily due to higher sales volumes driven by increased demand.
Sanofi collaboration revenue increased in the second quarter of 2026, compared to the second quarter of 2025, due to an increase in the Company's share of profits from the commercialization of antibodies, which were $2.033 billion and $1.282 billion in the second quarter of 2026 and 2025, respectively. The change in the Company's share of profits from the commercialization of antibodies was driven by higher profits primarily associated with an increase in Dupixent sales. In addition, the Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and will no longer reduce Sanofi collaboration revenue beginning in the third quarter of 2026.
Refer to Table 4 for a summary of collaboration revenue.
Operating Expenses
| | | GAAP | | % Change | | Non-GAAP**(a)** | | % Change |
| ($ in millions) | | Q2 2026 | | Q2 2025 | | | Q2 2026 | | Q2 2025 | |
| Research and development (R&D) | | $ | 1,632 | | | $ | 1,422 | | | 15 | % | | $ | 1,500 | | | $ | 1,283 | | | 17 | % |
| Acquired in-process research and development (IPR&D) | | $ | 127 | | | $ | 10 | | | ** | | | | * | | | | * | | | * | |
| Selling, general, and administrative (SG&A) | | $ | 662 | | | $ | 634 | | | 4 | % | | $ | 574 | | | $ | 542 | | | 6 | % |
| Cost of goods sold (COGS) | | $ | 361 | | | $ | 276 | | | 31 | % | | $ | 221 | | | $ | 222 | | | — | % |
| Gross margin on net product sales(b) | | | 78% | | | | 83% | | | | | | 87% | | | | 86% | | | |
| Cost of collaboration and contract manufacturing (COCM)(c) | | $ | 216 | | | $ | 255 | | | (15 | %) | | | * | | | | * | | | * | |
| |
| * GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been recorded |
| ** Percentage not meaningful or greater than 100% |
| |
-
GAAP and non-GAAP R&D expenses increased in the second quarter of 2026, compared to the second quarter of 2025, driven by the Company's mid- and late-stage clinical pipeline.
-
Acquired IPR&D expenses for the second quarter of 2026 included up-front and opt-in payments in connection with collaboration and licensing agreements.
-
GAAP gross margin on net product sales decreased in the second quarter of 2026, compared to the second quarter of 2025, primarily due to unabsorbed manufacturing costs as a result of the previously disclosed temporary interruption of bulk manufacturing production at the Company's facility in Limerick, Ireland. As of the end of the second quarter of 2026, bulk manufacturing production returned to normal levels. The interruption did not impact the availability of any of the Company's products.
Other Financial Information
GAAP other income (expense), net decreased in the second quarter of 2026, compared to the second quarter of 2025, primarily due to lower net gains on marketable and other securities.
In the second quarter of 2026, the Company's GAAP effective tax rate (ETR) was 15.1%, compared to 8.4% in the second quarter of 2025. The GAAP ETR increased in the second quarter of 2026, compared to the second quarter of 2025, primarily due to the net change in unrecognized tax benefits, as during the second quarter of 2025 the Company released liabilities associated with unrecognized tax benefits upon the settlement of an IRS audit. In the second quarter of 2026, the non-GAAP ETR was 15.5%, compared to 8.3% in the second quarter of 2025.
A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.
Capital Allocation
During the three and six months ended June 30, 2026, the Company repurchased $1.2 billion and $2.0 billion, respectively, of its common stock. As of June 30, 2026, $2.5 billion remained available for share repurchases under the Company's share repurchase programs.
In July 2026, the Company's board of directors declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on August 31, 2026 to shareholders of record as of August 18, 2026.
2026 Financial Guidance*
The Company's full year 2026 financial guidance consists of the following components:
| | | 2026 Guidance |
| | | Prior | | Updated |
| GAAP R&D | | $6.450–$6.680 billion | | $6.500–$6.635 billion |
| Non-GAAP R&D(a) | | $5.900–$6.100 billion | | $5.950–$6.050 billion |
| GAAP SG&A | | $2.860–$3.040 billion | | $2.830–$2.960 billion |
| Non-GAAP SG&A(a) | | $2.500–$2.650 billion | | $2.500–$2.600 billion |
| GAAP gross margin on net product sales | | 77%–78% | | 78%–79% |
| Non-GAAP gross margin on net product sales(a) | | 83%–84% | | 84%–85% |
| GAAP COCM | | $955 million–$1.035 billion | | $985 million–$1.035 billion |
| Non-GAAP COCM(a) | | $940 million–$1.020 billion | | $970 million–$1.020 billion |
| Capital expenditures | | $1.100–$1.200 billion | | $1.030–$1.100 billion |
| GAAP effective tax rate | | 12%–14% | | 13%–14% |
| Non-GAAP effective tax rate(a) | | 13%–15% | | 14%–15% |
| | | | | |
| * The Company's 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release |
| |
A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below:
| | | Projected Range |
| ($ in millions) | | Low | | High |
| GAAP R&D | | $ | 6,500 | | | $ | 6,635 | |
| Stock-based compensation expense | | | (550 | ) | | | (580 | ) |
| Other | | | — | | | | (5 | ) |
| Non-GAAP R&D(a) | | $ | 5,950 | | | $ | 6,050 | |
| | | | | |
| GAAP SG&A | | $ | 2,830 | | | $ | 2,960 | |
| Stock-based compensation expense | | | (330 | ) | | | (350 | ) |
| Other* | | | — | | | | (10 | ) |
| Non-GAAP SG&A(a) | | $ | 2,500 | | | $ | 2,600 | |
| | | | | |
| GAAP gross margin on net product sales | | | 78 | % | | | 79 | % |
| Stock-based compensation expense | | | 1 | % | | | 1 | % |
| Other** | | | 5 | % | | | 5 | % |
| Non-GAAP gross margin on net product sales(a) | | | 84 | % | | | 85 | % |
| | | | | |
| GAAP COCM | | $ | 985 | | | $ | 1,035 | |
| Temporary manufacturing interruption-related costs | | | (15 | ) | | | (15 | ) |
| Non-GAAP COCM(a) | | $ | 970 | | | $ | 1,020 | |
| | | | | |
| GAAP ETR | | | 13 | % | | | 14 | % |
| Income tax effect of GAAP to non-GAAP reconciling items | | | 1 | % | | | 1 | % |
| Income tax expense: Shortfall from stock-based compensation | | | (<1 | %) | | | (<1 | %) |
| Non-GAAP ETR(a) | | | 14 | % | | | 15 | % |
| | | | | |
| * Includes legal settlements and other costs |
| ** Includes intangible asset amortization and temporary manufacturing interruption-related costs |
| (a) | This press release uses non-GAAP R&D, non-GAAP SG&A, non-GAAP COGS, non-GAAP gross margin on net product sales, non-GAAP COCM, non-GAAP other income (expense), net, non-GAAP ETR, non-GAAP net income, non-GAAP net income per share, and free cash flow, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are computed by excluding certain non-cash and/or other items from the related GAAP financial measure. The Company also includes a non-GAAP adjustment for the estimated income tax effect of reconciling items. A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued or changes in the fair value of the Company's investments in equity securities) or items that are not associated with normal, recurring operations (such as acquisition and integration costs). Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. With respect to free cash flow, the Company believes that this non-GAAP measure provides a further measure of the Company's ability to generate cash flows from its operations. Additionally, the non-GAAP measures presented are intended to provide investors with an enhanced understanding of the financial performance of the Company's core business operations. However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by the Company should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP. |
| | |
| (b) | Gross margin on net product sales represents gross profit expressed as a percentage of total net product sales recorded by the Company. Gross profit is calculated as net product sales less cost of goods sold. |
| | |
| (c) | Corresponding reimbursements from collaborators and others for manufacturing product is recorded within revenues. |
| |
Conference****Call Information
Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2026 financial and operating results on Thursday, July 30, 2026, at 8:30 AM Eastern Time. Participants may access the conference call live via webcast, or register in advance and participate via telephone, on the "Investors and Media" page of Regeneron's website at www.regeneron.com. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using its proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.